September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
Semaglutide Cuts Cardiovascular Risk by 20% in Adults with Obesity, CVD and Without Diabetes
November 13th 2023AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.